Zurcher Kantonalbank Zurich Cantonalbank Has $13.63 Million Stock Position in Humana Inc. (NYSE:HUM)

Zurcher Kantonalbank Zurich Cantonalbank reduced its position in Humana Inc. (NYSE:HUM) by 19.9% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 53,738 shares of the insurance provider’s stock after selling 13,324 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Humana were worth $13,634,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. FPC Investment Advisory Inc. bought a new position in Humana in the 4th quarter valued at about $27,000. Centricity Wealth Management LLC bought a new position in Humana in the 4th quarter valued at about $30,000. Ashton Thomas Securities LLC bought a new position in Humana in the 3rd quarter valued at about $31,000. OFI Invest Asset Management bought a new position in Humana in the 4th quarter valued at about $33,000. Finally, Atwood & Palmer Inc. raised its holdings in Humana by 64.5% in the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after acquiring an additional 60 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Morgan Stanley lowered their price target on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 12th. Truist Financial increased their price target on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a report on Monday, January 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $283.00 target price on shares of Humana in a report on Wednesday, February 12th. StockNews.com cut shares of Humana from a “buy” rating to a “hold” rating in a report on Wednesday, March 5th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a report on Tuesday, February 18th. Twenty research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $285.68.

Humana Stock Performance

Shares of Humana stock opened at $249.32 on Thursday. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The firm has a market capitalization of $30.08 billion, a P/E ratio of 25.06, a P/E/G ratio of 2.05 and a beta of 0.57. The company’s 50 day moving average price is $271.59 and its two-hundred day moving average price is $281.42.

Humana (NYSE:HUM) last issued its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. On average, equities analysts forecast that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.42%. Humana’s dividend payout ratio (DPR) is presently 35.58%.

Insider Transactions at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.32% of the stock is owned by company insiders.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.